SEATTLE, Wa., June 21, 2017 Adaptive Biotechnologies, the leader in combining Next Generation Sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has partnered with Janssen Biotech, Inc. to utilize Adaptive’s NGS-based clonoSEQ Assay for measuring minimal residual disease (MRD) in patients with Multiple Myeloma (MM) who have been treated with DARZALEX (daratumumab). DARZALEX is a CD38-directed cytolytic antibody approved for the treatment of patients with relapsed or refractory MM.
BREAKING NEWS FROM ADAPTIVE
Press Releases | April 16, 2016
NEW ORLEANS, La., April 16, 2016 – Adaptive Biotechnologies, the leader in combining next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, along with its collaborators from institutions around the world, will present data demonstrating how Adaptive’s immunosequencing platform can be used as a novel oncology diagnostic to accurately and reliably quantify the density and clonality of Tumor Infiltrating Lymphocytes (TILs) to assess disease prognosis and response to therapy.
Press Releases | April 11, 2016
SEATTLE, Wa., April 11, 2016 – Adaptive Biotechnologies, the leader in combining next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces the appointment of Charles Sang to Senior Vice President, Diagnostics. Mr. Sang will be pivotal in leading the Company’s diagnostics business strategy for the clonoSEQ® Process which provides ultra-sensitive detection of minimal residual disease (MRD) in patients with lymphoid cancers, and may allow for earlier intervention for patients who may relapse.
Press Releases | March 15, 2016
SEATTLE, Wa., Adaptive Biotechnologies, the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces the appointment of Diego Miralles, M.D., as President of Adaptive Therapeutics. Most recently Dr. Miralles was the Global Head, Johnson & Johnson Innovation where he established the Johnson & Johnson Innovation Centers, JLABS, and Janssen Healthcare Innovation. Dr.
Press Releases | January 8, 2016
January 8, 2016 – New York, NY and Seattle, WA (U.S.) – Pfizer Inc. (NYSE: PFE) and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Under the terms of the agreement, Pfizer and Adaptive will seek to combine drug development and platform technology biomarker expertise to identify patients who may preferentially benefit from immunotherapy.
Press Releases | January 6, 2016
SEATTLE, Wa., January 6, 2016 – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announced today that Chad Robins, President, Chief Executive Officer and Co-founder, will present during the 34th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016 at 4:00 p.m. PST in San Francisco, CA.
Press Releases | December 7, 2015
ORLANDO, Fl., December 7, 2015 – Adaptive Biotechnologies, the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and collaborators from several academic institutions will today present data showing that MRD testing using the company’s clonoSEQ® Process at one year post-transplant can predict both relapse-free and overall survival (RFS and OS, respectively) in patients with chronic lymphocytic leukemia (CLL) who are treated with reduced intensity conditioning followed by allogeneic (donor)
Press Releases | December 6, 2015
ORLANDO, Fl., December 6, 2015 – Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and collaborators from the Dana-Farber Cancer Institute and University Hospital in Toulouse, France will today present data showing that Adaptive’s NGS-based MRD assessment method (available for clinical use through Adaptive’s CLIA-certified laboratory as the clonoSEQ® Process) sensitively detects minute traces of myeloma in clinical trial patients and predicts outcomes b
Press Releases | December 5, 2015
ORLANDO, Fl., December 5, 2015 – Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and its collaborators will present data today at the American Society of Hematology (ASH) Annual Meeting showing that the clonoSEQ® minimal residual disease (MRD) Test can predict which multiple myeloma (MM) patients undergoing autologous (“self”) transplant will benefit from post-transplant treatment with novel therapies.
Press Releases | December 4, 2015
SEATTLE, Wa., December 4, 2015 – Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, today announced that it is expanding the clonoSEQ® Process to include minimal residual disease (MRD) analysis of cells harvested from patients with lymphoid cancers being prepared for autologous (“self”) stem cell transplant.
Press Releases | November 5, 2015
Adaptive Biotechnologies, the leader in combining next-generation sequencing and expert bioinformatics to profile T-cell and B-cell receptors of the adaptive immune system, and its collaborators from academic institutions around the world will share data further demonstrating the validity and prognostic value of the clonoSEQ® Process for minimal residual disease (MRD) assessment in lymphoid cancers in three oral and eight poster presentations, encompassing six different blood cancer subtypes, at the American Society of Hematology (ASH) Annual Meeting, December 5-8, 2015 in Orland